Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma.

Josefsson SE, Beiske K, Blaker YN, Førsund MS, Holte H, Østenstad B, Kimby E, Köksal H, Wälchli S, Bai B, Smeland EB, Levy R, Kolstad A, Huse K, Myklebust JH.

Cancer Immunol Res. 2019 Mar;7(3):355-362. doi: 10.1158/2326-6066.CIR-18-0351. Epub 2019 Jan 18.

2.

T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.

Josefsson SE, Huse K, Kolstad A, Beiske K, Pende D, Steen CB, Inderberg EM, Lingjærde OC, Østenstad B, Smeland EB, Levy R, Irish JM, Myklebust JH.

Clin Cancer Res. 2018 Feb 15;24(4):870-881. doi: 10.1158/1078-0432.CCR-17-2337. Epub 2017 Dec 7.

3.

CD155T/TIGIT Signaling Regulates CD8+ T-cell Metabolism and Promotes Tumor Progression in Human Gastric Cancer.

He W, Zhang H, Han F, Chen X, Lin R, Wang W, Qiu H, Zhuang Z, Liao Q, Zhang W, Cai Q, Cui Y, Jiang W, Wang H, Ke Z.

Cancer Res. 2017 Nov 15;77(22):6375-6388. doi: 10.1158/0008-5472.CAN-17-0381. Epub 2017 Sep 7.

4.

TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.

Chauvin JM, Pagliano O, Fourcade J, Sun Z, Wang H, Sander C, Kirkwood JM, Chen TH, Maurer M, Korman AJ, Zarour HM.

J Clin Invest. 2015 May;125(5):2046-58. doi: 10.1172/JCI80445. Epub 2015 Apr 13.

5.

The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.

Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y, Park S, Javinal V, Chiu H, Irving B, Eaton DL, Grogan JL.

Cancer Cell. 2014 Dec 8;26(6):923-937. doi: 10.1016/j.ccell.2014.10.018. Epub 2014 Nov 26.

6.

PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+ T-cell Function.

Whelan S, Ophir E, Kotturi MF, Levy O, Ganguly S, Leung L, Vaknin I, Kumar S, Dassa L, Hansen K, Bernados D, Murter B, Soni A, Taube JM, Fader AN, Wang TL, Shih IM, White M, Pardoll DM, Liang SC.

Cancer Immunol Res. 2019 Feb;7(2):257-268. doi: 10.1158/2326-6066.CIR-18-0442. Epub 2019 Jan 18.

PMID:
30659054
7.

TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection.

Chew GM, Fujita T, Webb GM, Burwitz BJ, Wu HL, Reed JS, Hammond KB, Clayton KL, Ishii N, Abdel-Mohsen M, Liegler T, Mitchell BI, Hecht FM, Ostrowski M, Shikuma CM, Hansen SG, Maurer M, Korman AJ, Deeks SG, Sacha JB, Ndhlovu LC.

PLoS Pathog. 2016 Jan 7;12(1):e1005349. doi: 10.1371/journal.ppat.1005349. eCollection 2016 Jan.

8.

CD8+T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patients.

Wang M, Bu J, Zhou M, Sido J, Lin Y, Liu G, Lin Q, Xu X, Leavenworth JW, Shen E.

Clin Immunol. 2018 May;190:64-73. doi: 10.1016/j.clim.2017.08.021. Epub 2017 Sep 8.

PMID:
28893624
9.

Increased Coexpression of PD-1, TIGIT, and KLRG-1 on Tumor-Reactive CD8+ T Cells During Relapse after Allogeneic Stem Cell Transplantation.

Hutten TJA, Norde WJ, Woestenenk R, Wang RC, Maas F, Kester M, Falkenburg JHF, Berglund S, Luznik L, Jansen JH, Schaap N, Dolstra H, Hobo W.

Biol Blood Marrow Transplant. 2018 Apr;24(4):666-677. doi: 10.1016/j.bbmt.2017.11.027. Epub 2017 Dec 26.

10.

Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.

Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM.

Clin Cancer Res. 2011 Jul 1;17(13):4232-44. doi: 10.1158/1078-0432.CCR-10-2660. Epub 2011 May 3.

11.

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM.

Hung AL, Maxwell R, Theodros D, Belcaid Z, Mathios D, Luksik AS, Kim E, Wu A, Xia Y, Garzon-Muvdi T, Jackson C, Ye X, Tyler B, Selby M, Korman A, Barnhart B, Park SM, Youn JI, Chowdhury T, Park CK, Brem H, Pardoll DM, Lim M.

Oncoimmunology. 2018 May 24;7(8):e1466769. doi: 10.1080/2162402X.2018.1466769. eCollection 2018.

12.

Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase.

Inozume T, Yaguchi T, Furuta J, Harada K, Kawakami Y, Shimada S.

J Invest Dermatol. 2016 Jan;136(1):255-63. doi: 10.1038/JID.2015.404.

13.

CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function.

Mittal D, Lepletier A, Madore J, Aguilera AR, Stannard K, Blake SJ, Whitehall VLJ, Liu C, Bettington ML, Takeda K, Long GV, Scolyer RA, Lan R, Siemers N, Korman A, Teng MWL, Johnston RJ, Dougall WC, Smyth MJ.

Cancer Immunol Res. 2019 Apr;7(4):559-571. doi: 10.1158/2326-6066.CIR-18-0637. Epub 2019 Mar 20.

PMID:
30894377
14.

Melanoma Cells Control Anti-Melanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase.

Inozume T, Yaguchi T, Furuta J, Harada K, Kawakami Y, Shimada S.

J Invest Dermatol. 2015 Oct 12. doi: 10.1038/jid.2015.404. [Epub ahead of print]

PMID:
26458009
15.

Expression of the immune checkpoint receptor TIGIT in Hodgkin's lymphoma.

Li W, Blessin NC, Simon R, Kluth M, Fischer K, Hube-Magg C, Makrypidi-Fraune G, Wellge B, Mandelkow T, Debatin NF, Pott L, Höflmayer D, Lennartz M, Sauter G, Izbicki JR, Minner S, Büscheck F, Uhlig R, Dum D, Krech T, Luebke AM, Wittmer C, Jacobsen F, Burandt E, Steurer S, Wilczak W, Hinsch A.

BMC Cancer. 2018 Dec 4;18(1):1209. doi: 10.1186/s12885-018-5111-1.

16.

Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors.

Xu Y, Cui G, Jiang Z, Li N, Zhang X.

Oncol Lett. 2019 Mar;17(3):2960-2968. doi: 10.3892/ol.2019.9910. Epub 2019 Jan 9.

17.

Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity.

Zhang Q, Bi J, Zheng X, Chen Y, Wang H, Wu W, Wang Z, Wu Q, Peng H, Wei H, Sun R, Tian Z.

Nat Immunol. 2018 Jul;19(7):723-732. doi: 10.1038/s41590-018-0132-0. Epub 2018 Jun 18.

PMID:
29915296
18.

CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART.

Fromentin R, Bakeman W, Lawani MB, Khoury G, Hartogensis W, DaFonseca S, Killian M, Epling L, Hoh R, Sinclair E, Hecht FM, Bacchetti P, Deeks SG, Lewin SR, Sékaly RP, Chomont N.

PLoS Pathog. 2016 Jul 14;12(7):e1005761. doi: 10.1371/journal.ppat.1005761. eCollection 2016 Jul.

19.

DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy.

Sanchez-Correa B, Valhondo I, Hassouneh F, Lopez-Sejas N, Pera A, Bergua JM, Arcos MJ, Bañas H, Casas-Avilés I, Durán E, Alonso C, Solana R, Tarazona R.

Cancers (Basel). 2019 Jun 23;11(6). pii: E877. doi: 10.3390/cancers11060877. Review.

20.

Expression of LAG-3 defines exhaustion of intratumoral PD-1+ T cells and correlates with poor outcome in follicular lymphoma.

Yang ZZ, Kim HJ, Villasboas JC, Chen YP, Price-Troska T, Jalali S, Wilson M, Novak AJ, Ansell SM.

Oncotarget. 2017 May 29;8(37):61425-61439. doi: 10.18632/oncotarget.18251. eCollection 2017 Sep 22.

Supplemental Content

Support Center